GlassScriptPhysician profile
Paula Radon
NPI 1528081759
$610.61
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $125.56 | 2019 | |
| Amag Pharmaceuticals, INC. | $98.74 | 2019 | |
| Therapeuticsmd, INC. | $74.46 | 2019 | |
| Allergan, INC. | $71.84 | 2019 | |
| Merck Sharp & Dohme LLC | $57.63 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.11 | 2019 | |
| Pfizer INC. | $34.19 | 2019 | |
| Mylan Pharmaceuticals INC. | $30.05 | 2019 | |
| Lupin INC. | $25.17 | 2019 | |
| Asensus Surgical, INC. | $14.95 | 2019 | |
| Exeltis, USA INC. | $11.99 | 2019 | |
| Duchesnay USA Incorporated | $11.71 | 2019 | |
| Millicent US INC | $11.21 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Radon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.